SGHT SIGHT SCIENCES INC

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually.

Sight Sciences’ management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at .

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit for more information. 

Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

© 2025 Sight Sciences. All rights reserved.

Media contact:

Investor contact:

Philip Taylor

Gilmartin Group

415.937.5406



EN
25/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SIGHT SCIENCES INC

 PRESS RELEASE

Sight Sciences Announces Fee Schedule Establishment from Novitas Solut...

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. (Novitas) and First Coast Service Options, Inc. (FCSO), each establ...

 PRESS RELEASE

Sight Sciences Announces Publication of a Systematic Literature Review...

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucoma MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on d...

 PRESS RELEASE

Sight Sciences Announces the OMNI® Surgical System to be Included in U...

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today a...

 PRESS RELEASE

Sight Sciences Announces Recognition of the TearCare® System in TFOS D...

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that its T...

 PRESS RELEASE

Sight Sciences to Present at the Upcoming Morgan Stanley Global Health...

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Sight Sciences’ management is scheduled to present on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET. Inte...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch